What IDBiologics does

IDBiologics is a privately held clinical-stage biotechnology company founded in 2017 and headquartered in Nashville, Tennessee, that develops fully human monoclonal antibodies for the prevention and treatment of infectious diseases. The company was founded from the laboratory of Professor James Crowe at Vanderbilt University Medical Center, whose research underpins the company's proprietary fully human mAb platform for rapid discovery and optimization of broad, potent therapeutic antibodies with neutralizing activity against diverse viral targets.

IDBiologics' pipeline comprises six clinical lead candidate molecules, each with animal proof-of-concept: BK virus (BKV) antibodies for immunocompromised transplant patients; a two-mAb pan-influenza combination engineered for approximately six-month duration and ~90% neutralizing efficacy against influenza A and B including pre-pandemic strains; RSV-199, a single cross-neutralizing antibody for RSV and HMPV; IDB002 for Zika virus pre-exposure prophylaxis; a two-mAb Rift Valley fever virus (RVFV) therapy; and an EV-D68 program for pediatric respiratory enterovirus.

The company's business model centers on non-dilutive U.S. Government funding, with five USG grants totaling $38 million and a 2023 Department of Defense contract for RVFV antibody development through Phase 1. Revenue-generating mechanisms are limited to government contracts and grants at present, with future commercial product sales, licensing, and royalties as longer-term monetization pathways. Key customers are U.S. government biodefense agencies, with downstream commercial targets including healthcare providers serving immunocompromised and elderly patients and global public health organizations. Leadership includes Co-Founder and CEO Ken Kelley, Co-Founder and President Chuck Haines, Chief Business Officer Felix Karim, and Founder James Crowe.

Name

IDBiologics

Legal name

IDBiologics, Inc.

Website

https://idbiologics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

IDBiologics is a Nashville-based clinical-stage biotechnology company founded in 2017 that develops fully human monoclonal antibodies for preventing and treating infectious diseases, serving U.S. government biodefense agencies and targeting immunocompromised and elderly patient populations.

Ownership category

akta.pro rank

Product category

Infectious Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Monoclonal antibody therapeutics
• Infectious disease prevention
• Biodefense countermeasures
• Antibody drug development
• Viral neutralization research

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Government Contracts and Grants: IDBiologics pursues non-dilutive funding through U.S. government grants and contracts, including Department of Defense contracts for medical countermeasures development. The company has secured 5 USG grants totaling $38 million and a DOD contract for RVFV antibody development through Phase 1.
2. Commercial Product Development: Development of monoclonal antibody therapeutics for commercial markets targeting infectious diseases including BKV, pan-influenza, RSV/HMPV, and other viral threats. Public health programs funded by non-dilutive grants help de-risk formulation technologies for both public health and commercial mAb products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

IDBiologics discovers and develops fully human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. Leveraging a platform spun out of Professor James Crowe's laboratory at Vanderbilt University Medical Center, the company advances a pipeline of six clinical lead candidate molecules targeting BKV, pan-influenza (A+B), RSV/HMPV, Zika virus (ZIKV), Rift Valley fever virus (RVFV), and Enterovirus D68 (EV-D68). Programs span both commercial indications and global public health / biodefense applications.

Product overview

IDBiologics is developing a pipeline of human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. The company's portfolio includes six clinical lead candidate molecules targeting diverse pathogens: BKV (BK virus) for transplant patients, Pan-Influenza (A+B) combining two mAbs with six-month duration, RSV-199 for RSV/HMPV co-infection, IDB002 for Zika virus prophylaxis, RVFV (Rift Valley Fever virus) as a biothreat countermeasure, and EV-D68 for pediatric respiratory infection. The platform was founded from Professor James Crowe's laboratory at Vanderbilt University Medical Center and enables rapid discovery and optimization of broad, potent therapeutic mAbs with neutralizing activity.

Differentiator

Problem solved

Functional benefit

Products and services

• BKV (BK Virus) Program Panel of anti-BKV monoclonal antibodies including a lead and back-up clinical candidate developed as prevention of BKV viremia/DNAemia and BKV-associated nephropathy (BKVAN) in immunocompromised patients, particularly kidney transplant recipients.
• Pan-Influenza (A+B) Program Combination of two ultra-potent human monoclonal antibodies engineered for approximately six-month duration of action, designed to achieve about 90% neutralizing efficacy against pan-influenza A and B strains, including pre-pandemic H5N1 and H7N9 strains.
• RSV-199 (RSV/HMPV Program) Single human monoclonal antibody, RSV-199, that cross-neutralizes both RSV A and B strains and HMPV, offering enhanced protection demonstrated in cotton rat models supporting broad neutralization and therapeutic potential.
• IDB002 (Zika Virus Program) Ultra-potent neutralizing monoclonal antibody being developed as an off-the-shelf pre-exposure prophylaxis (PrEP) against Zika virus infection, addressing the risk of Congenital Zika Syndrome in developing fetuses.
• RVFV (Rift Valley Fever Virus) Program Two human monoclonal antibodies that directly inhibit RVFV replication without binding to the same critical residues, engineered with extended half-life for combination therapeutic and preventive use against this emerging arbovirus with pandemic potential. Developed with U.S. Department of Defense funding.
• EV-D68 (Enterovirus D68) Program Monoclonal antibody program targeting Enterovirus D68, a respiratory enterovirus with no available vaccines or treatments, primarily affecting children.

Quantifiable outcome

• 90% neutralizing efficacy expected against pan-influenza (A+B) strains
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• United States Department of Defense (DOD)coreStrategic or Co-development Partner · 12 May 2023IDBiologics entered into a contract with the U.S. Department of Defense to accelerate development of human mAbs as medical countermeasures against targeted infectious disease threats. The first project is a two-antibody medicine to prevent RVFV infection, with the initial phase funding preclinical development through completion of Phase 1 human clinical studies. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
• Vanderbilt University Medical Center (VUMC)coreStrategic or Co-development PartnerVanderbilt University licensed the rights to RVFV antibodies to IDBiologics. Professor James Crowe and his laboratory at VUMC lead preclinical assessment of neutralizing activity, while IDBiologics leads preclinical safety and toxicology studies, manufacturing process development, production for clinical trials, and execution of Phase 1 clinical trial. The company was founded from Professor Crowe's laboratory.
• Global Pandemic Prevention and Biodefense Center (GPPBC)supportingStrategic or Co-development PartnerThe Global Pandemic Prevention and Biodefense Center is assisting with planning for late-stage development, stockpiling, and long-term use of the RVFV antibody medicine, although those activities are outside the scope of the DOD contract.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vir Biotechnology: Clinical-stage immunology company developing monoclonal antibodies for serious infectious diseases including influenza (VIR-2482) and COVID-19 (sotrovimab). Highly comparable to IDBiologics in therapeutic modality, infectious-disease focus, and target overlap on pan-influenza and respiratory pathogens.
• IGM Biosciences: Clinical-stage biotech developing engineered IgM and IgG antibodies for infectious diseases and immune-mediated conditions, with active programs in COVID-19 and other viral targets. Comparable antibody-platform biotech at similar clinical stage targeting overlapping infectious-disease indications.
• Mapp Biopharmaceutical: Clinical-stage biotech specializing in monoclonal antibody countermeasures for high-consequence infectious diseases and biothreats, including FDA-approved Ebanga (ansuvimab) for Ebola. Highly comparable mission and biodefense focus to IDBiologics with similar government contract-based funding model.

Broad incumbents

• Regeneron Pharmaceuticals: Large established biotech with a market-leading antibody platform (VelocImmune) and multiple approved/infectious-disease mAbs including REGN-COV2 for COVID-19 and Ebola antibody treatments. Represents the gold-standard incumbent that IDBiologics' technology platform is positioned alongside in infectious-disease mAbs.
• AstraZeneca: Global biopharmaceutical company with significant infectious-disease mAb franchise including Evusheld (tixagevimab/cilgavimab) for COVID-19 pre-exposure prophylaxis. Comparable as a manufacturer of antibody-based prophylaxis for vulnerable populations and a competitor for biodefense and pandemic preparedness stockpiling programs.
• Eli Lilly: Large pharmaceutical company that developed bebtelovimab and other infectious-disease mAbs targeting COVID-19 and other pathogens. Comparable as a vertically integrated mAb developer pursuing infectious-disease indications, including seasonal flu and biodefense-adjacent opportunities.

Emerging players

• SAB Biotherapeutics: Clinical-stage biotech developing polyclonal and engineered human antibodies for infectious diseases including influenza and emerging viral threats, with DARPA and BARDA funding history. Partially comparable platform with adjacent technology targeting similar biodefense indications.
• Arcturus Therapeutics: Clinical-stage mRNA and infectious-disease biotech with active programs in influenza, COVID-19, and other viral pathogens. Indirect comparator pursuing infectious-disease prophylaxis through a different modality (mRNA) targeting comparable seasonal and pandemic preparedness indications.
• Humanigen (formerly): Small clinical-stage biotech developing monoclonal antibodies for infectious and inflammatory diseases (lenzilumab for COVID-19). Comparable as a small-cap mAb developer pursuing infectious-disease indications through a similar government- and partner-funded clinical-development model, though Humanigen's pipeline struggled commercially.

Others

• Adimab: Industry-leading antibody discovery platform company enabling pharma partners to discover human mAbs. Comparable as a fully human antibody discovery engine; functions as an enabling platform rather than a downstream competitor, but represents an alternative approach to mAb generation that biotech sponsors may choose instead of internal platforms like IDBiologics'.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/idbiologics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDBiologics